Madrigal Pharmaceuticals, Inc. (MDGL) financials: revenue, earnings and cash flow
Fiscal 2016–2025 + TTM · from SEC filings · data as of November 13, 2026
Summary
Net income in fiscal 2025 was -$288M, a net margin of -30.1%; the best year in this period was 2016 with -$26M.
Over the twelve months to September 30, 2026, revenue was $1.4B and net income -$155M.
Free cash flow was -$190M in fiscal 2025 and positive in 0 of the 10 years shown.
The diluted share count rose 331% over the period (dilution).
Revenue, profit and cash flow by year
Income statement
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $1.4B | $958M | $180M | $0 | $0 | $0 | $0 | $0 | $0 | $0 | — |
| Gross profit | — | — | $174M | $0 | $0 | — | — | — | — | — | — |
| Operating income | -$153M | -$300M | -$498M | -$380M | -$294M | -$242M | -$207M | -$95M | -$41M | -$32M | -$25M |
| Net income | -$155M | -$288M | -$466M | -$374M | -$295M | -$242M | -$202M | -$84M | -$33M | -$31M | -$26M |
| EPS (diluted) | $-5.85 | $-12.85 | $-21.90 | $-19.99 | $-17.23 | $-14.63 | $-13.09 | $-5.45 | $-2.22 | $-2.54 | $-5.07 |
| R&D | $388M | $389M | $237M | $272M | $245M | $205M | $185M | $72M | $25M | $24M | $16M |
| Revenue growth | — | +432.1% | — | — | — | — | — | — | — | — | — |
Cash flow
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$157M | -$190M | -$456M | -$324M | -$225M | -$184M | -$158M | -$42M | -$26M | -$22M | -$18M |
| Capital spending | -$12M | -$467000 | -$1M | -$1M | -$217000 | -$209000 | -$334000 | -$172000 | -$22000 | -$125000 | -$3000 |
| Free cash flow | -$169M | -$190M | -$457M | -$326M | -$225M | -$184M | -$158M | -$42M | -$26M | -$22M | -$18M |
| Dividends paid | — | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Buybacks | — | — | — | — | — | — | — | — | — | — | — |
| Stock-based pay | $134M | $98M | $80M | $50M | $32M | $27M | $21M | $23M | $13M | $3M | $8M |
Balance sheet
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash | — | $984M | $926M | $634M | $359M | $270M | $284M | $439M | $484M | $192M | $19M |
| Debt | — | $348M | $120M | $117M | $70M | $797000 | $786000 | $676000 | — | — | — |
| Equity | — | $603M | $754M | $405M | $197M | $196M | $240M | $417M | $477M | $182M | $36M |
| Total assets | — | $1.3B | $1.0B | $641M | $363M | $273M | $287M | $442M | $485M | $192M | $41M |
| Shares (diluted) | 30M | 22M | 21M | 19M | 17M | 17M | 15M | 15M | 15M | 12M | 5M |
Margins and returns
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross margin | — | — | 96.5% | — | — | — | — | — | — | — | — |
| Operating margin | -10.7% | -31.3% | -276.4% | — | — | — | — | — | — | — | — |
| Net margin | -10.9% | -30.1% | -258.6% | — | — | — | — | — | — | — | — |
| FCF margin | -11.8% | -19.8% | -253.7% | — | — | — | — | — | — | — | — |
| ROIC | — | -24.9% | -45.0% | -57.5% | -86.7% | -97.3% | -67.8% | -18.0% | -6.7% | -13.9% | -54.7% |
| ROE | — | -47.8% | -61.8% | -92.2% | -149.6% | -123.3% | -84.3% | -20.2% | -6.9% | -17.1% | -72.5% |
Frequently asked questions
What is Madrigal Pharmaceuticals’s annual revenue?
$958M in fiscal 2025 and $1.4B over the twelve months to September 30, 2026.
How much profit does Madrigal Pharmaceuticals make?
Net income was -$288M in fiscal 2025 (net margin -30.1%).
Is Madrigal Pharmaceuticals’s revenue growing?
Yes: revenue rose 432.1% in fiscal 2025 compared with the year before.
From the company’s 10-K and 10-Q filings with the SEC; per-share figures adjusted for stock splits. Rebuilt daily. Not investment advice.